軸性脊椎関節炎:アジア太平洋疫学予測2028

◆英語タイトル:Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028
◆商品コード:GDT20FB0236
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年11月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,495 ⇒換算¥384,450見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD6,990 ⇒換算¥768,900見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD10,485 ⇒換算¥1,153,350見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Axial Spondyloarthritis: Epidemiology Forecast in Asia-Pacific Markets to 2028
Summary

Axial spondyloarthritis (AxSpA) is a condition characterized by predominant inflammation in the spine and/or sacroiliac joints, with inflammatory back pain and stiffness that may be improved with exercise. Based on sacroiliac changes on conventional radiographs, AxSpA is classified into radiographic (r-AxSpA) or nonradiographic (nr-AxSpA) depending on the presence or absence of radiographic changes at the sacroiliac joints. Patients traditionally classified as ankylosing spondylitis (AS) would be considered as r-AxSpA. Some of nr-AxSpA progress to AS and some do not (Sieper et al., 2002; Kiltz et al., 2012; Wallis et al., 2013). AS has a genetic association with the HLA-B27 risk allele (Sieper et al., 2002; Dean et al., 2014).

GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of AxSpA in the 5GM. GlobalData’s epidemiological analysis provides country-specific forecasts for the diagnosed prevalent cases of AS and nr-AxSpA in the 5GM during 2018-2028 using two different approaches: forecast based on data obtained through primary market research (PMR) (base scenario), and forecast based on data obtained from secondary research (alternate scenario).

The following data describes diagnosed prevalent cases of AS and nr-AxSpA in the 5GM using base scenario, where the forecast is based on data obtained from PMR. In the 5GM, the diagnosed prevalent cases of AS will increase from 3,472,166 cases in 2018 to 4,28,719 cases in 2028, at an Annual Growth Rate (AGR) of 3.33%, and the diagnosed prevalent cases of nr-AxSpA will increase from 2,579,931 cases in 2018 to 3,375,427 cases in 2028, at an AGR of 3.08%.

Scope

- The Axial Spondyloarthritis Epidemiology Report provides an overview of the risk factors and global trends of AxSpA in the five growth markets (5GM: Australia, China [urban], India, South Korea, and Japan).
- Base Scenario: This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of AS and nr-AxSpA for both sexes and ages ≥18 years in the 5GM.
- Alternate Scenario: Additionally, a 10-year epidemiological forecast for the diagnosed prevalent cases of AS and nr-AxSpA segmented by age (18-19 years, 20-29 years, 30-44 years, 45-59 years, 60-74 years, 75-79 years, 80-84 years, and 85 years and older) and sex. The report also provides the forecast for diagnosed prevalent cases of AS segmented by HLA-B27 seropositivity status in the 5GM.
- The axial spondyloarthritis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.

Reasons to buy

The AxSpA Epidemiology series will allow you to –
- Develop business strategies by understanding the trends shaping and driving the global AxSpA market.
- Quantify patient populations in the global AxSpA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AxSpA therapeutics in each of the markets covered.
- Understand magnitude of AxSpA by radiographic and nonradiographic population.

【レポートの目次】

Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Axial Spondyloarthritis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS – Base Scenario
3.4.3 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA – Base Scenario
3.4.4 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of AS – Alternative Scenario
3.4.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Nr-AxSpA – Alternative Scenario
3.4.6 Forecast Assumptions and Methods, HLA-B27 Seropositivity Among Diagnosed AS Patients
3.5 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) – Base Scenario
3.5.1 Diagnosed Prevalent Cases of AS
3.5.2 Diagnosed Prevalent Cases of Nr-AxSpA
3.6 Epidemiological Forecast for AS and Nr-AxSpA (2018-2028) – Alternative Scenario
3.6.1 Diagnosed Prevalent Cases of AS
3.6.2 Age-Specific Diagnosed Prevalent Cases of AS
3.6.3 Sex-Specific Diagnosed Prevalent Cases of AS
3.6.4 Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity
3.6.5 Diagnosed Prevalent Cases of Nr-AxSpA
3.6.6 Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA
3.6.7 Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA
3.7 Discussion
3.7.1 Epidemiological Forecast Insight
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4 Appendix

List of Tables
Table 1: Risk Factors and Comorbidities for AS
Table 2: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures
Figure 1: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 and 2028 - Base Scenario
Figure 2: 5GM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, Both Sexes, N, 2018 and 2028 - Base Scenario
Figure 3: 5GM, Diagnosed Prevalence (%) of AxSpA, Both Sexes, Ages ≥18 Years, 2008-2028 - Base Scenario
Figure 4: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Base Scenario
Figure 5: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-AxSpA - Base Scenario
Figure 6: 5GM, Sources Used, Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 7: 5GM, Sources Used, Diagnosed Prevalent Cases of Nr-AxSpA - Alternative Scenario
Figure 8: 5GM, Sources Used, HLA-B27 Seropositivity Data Among the Diagnosed Prevalent Cases of AS - Alternative Scenario
Figure 9: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 10: 5GM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Base Scenario
Figure 11: 5GM, Diagnosed Prevalent Cases of AS, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 12: 5GM, Age-Specific Diagnosed Prevalent Cases of AS, Both Sexes, N, 2018 - Alternative Scenario
Figure 13: 5GM, Sex-Specific Diagnosed Prevalent Cases of AS, Ages ≥18 Years, N, 2018 - Alternative Scenario
Figure 14: 5GM, Diagnosed Prevalent Cases of AS by HLA-B27 Seropositivity, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 15: 5GM, Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, Both Sexes, N, 2018 - Alternative Scenario
Figure 16: 5GM, Age-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Both Sexes, N, 2018 - Alternative Scenario
Figure 17: 5GM, Sex-Specific Diagnosed Prevalent Cases of Nr-AxSpA, Ages ≥18 Years, N, 2018 - Alternative Scenario

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[軸性脊椎関節炎:アジア太平洋疫学予測2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆